NCT00907062

Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents

Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents: an Open Label Pilot Clinical Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Toronto · Academic / Other
• Sex: All
• Age: 12 Years – 18 Years
• Healthy volunteers: Accepted

Summary

Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. One study investigating the use of Ginkgo biloba for the treatment of vitiligo in adults reports effectiveness, but has significant flaws. We endeavor to conduct an open label pilot clinical trial replicating the previous trial on 12 adolescents 12 to 18 years old. The purpose of the pilot is to test the feasibility of recruitment and patient retention, variability of outcome measures, and identify major safety concerns. The pilot will use 60 mg of standardized G. biloba two times per day (BID) for 12 weeks. The primary outcome will be the validated Vitiligo European Task Force (VETF) evaluation form, secondary outcomes will include the Vitiligo Area Scoring Index (VASI), assess repigmentation via photographs, and will monitor and report adverse reactions.

Conditions

• Vitiligo Vulgaris

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Ginkgo biloba	60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-10-01
• Completion: 2009-11-01
• First posted: 2009-05-22
• Last updated: 2010-07-08

Locations

1 site across 1 country: Canada